Prolight Diagnostics (“Prolight”) today announces that the company’s subsidiary Psyros Diagnostics (“Psyros”) has submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain.
The first application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using Prolight’s unique single molecule counting technology, multiplexing can be carried out in a single drop of blood on a sensor without needing to split the sample into separate areas. The second application uses a similar approach to allow the measurement of the same biomarker at both very low and very high concentrations simultaneously.
One potential application of multiplexing is the development of panels which measure biomarkers corresponding to several diseases having similar confounding symptoms. Multiplexing also allows the measurement of several biomarkers which together have stronger power to detect specific diseases.
Furthermore, the benefit of the technology is that the sample size remains extremely small, and that the sensor is easy to manufacture, yet also offering the ability to detect very low concentrations of biomarkers with high specificity.
Prolight’s subsidiary, Psyros, has previously filed three patent applications for its unique digital immunoassay technology. The first application has completed the PCT phase and is now being pursued in different territories worldwide. The second and third application are in the PCT phase. The two new patent applications will enter the PCT phase in 2024.
About PCT and patent application processes
Patent Cooperation Treaty (PCT) is an international agreement that allows you to obtain, with a single application, in one language, a novelty search and preliminary patentability assessment conducted by one authority for approximately 150 countries. For a PCT application to lead to a patent in a particular country (or territory, such as the EU), the application must be prosecuted at each respective patent office.
